Takotsubo syndrome as an outcome of the use of checkpoint inhibitor therapy in patients with COVID-19

• Published in: Biochemical pharmacology 2024-08, Vol.226, p.116388, Article 116388
• Main Authors: Simões, Júlia Leão Batista, Braga, Geórgia de Carvalho, Coiado, João Victor, Scaramussa, Alexandre Bachietti, Rodrigues, Ana Paula Barasuol, Bagatini, Margarete Dulce
• Format: Article
• Language: English
• Subjects: Checkpoint inhibitor therapy; COVID-19; COVID-19 - complications; COVID-19 Drug Treatment; Cytokine storm; Humans; Immune Checkpoint Inhibitors - adverse effects; Immune Checkpoint Inhibitors - therapeutic use; SARS-CoV-2 - drug effects; Takotsubo; Takotsubo Cardiomyopathy - drug therapy
• ISSN: 0006-2952; 1873-2968; 1873-2968
• DOI: 10.1016/j.bcp.2024.116388

[Display omitted] Takotsubo Syndrome (TS) is a heart disease caused by extreme exposure of the body to physical or psychological stress. In the context of COVID-19, the virus can be a significant source of stress, with particular attention being paid to the cytokine storm as a cause of damage to the body. New research shows that the production of specific cytokines is linked to the activation of immune checkpoint proteins such as PD-1, PD-L1, and CTLA-4 on T cells. Although initially beneficial in combating infections, it can suppress defense and aid in disease progression. Therefore, checkpoint inhibitor therapy has been highlighted beyond oncological therapies, given its effectiveness in strengthening the immune system. However, this treatment can lead to excessive immune responses, inflammation, and stress on the heart, which can cause Takotsubo Syndrome in patients. Several studies investigate the direct link between this therapy and cardiac injuries in these patients, which can trigger TS. From this perspective, we must delve deeper into this treatment and consider its effects on the prognosis against SARS-CoV-2 infection.